Tissue Microarray Market Size and Trends

The tissue microarray market size is forecast to increase by USD 2.25 billion at a CAGR of 5.8% between 2023 and 2028. The market is experiencing significant growth due to the increasing number of cancer cases worldwide and the rising popularity of precision and personalized medicines. Automation in TMA technology is a major trend, increasing sample throughput and improving data analysis capabilities. Imaging techniques, such as digital pathology, are also gaining traction in the market, enabling more accurate and efficient analysis of tissue samples. The high cost of instruments is a challenge, but the potential for biomarker research, drug development, and clinical trials in various fields, including neurology and cardiology, is driving market growth. Antibodies and imaging techniques are essential tools in TMA research, allowing for the identification and analysis of specific biomarkers in tissue samples. In the field of oncology, TMAs are particularly valuable for understanding the progression and response to the treatment of various types of cancer.

 Request Free Sample

The market holds significant importance in the field of molecular pathology, particularly in the context of oncology research. TMA is a valuable technology used for the analysis of gene expression, protein localization, and molecular markers in various clinical settings. In molecular pathology, TMA plays a crucial role in understanding tumor heterogeneity and identifying biomarkers for clinical outcomes, therapeutic targets, and prognostic indicators. The ability to analyze protein expression through techniques such as immunohistochemistry (IHC) and spectroscopic analysis provides valuable insights into drug efficacy and cancer progression. TMA is particularly useful in cancer research, where it enables high-throughput screening of large numbers of tissue samples. Paraffin blocks and tissue cores are used to construct TMAs, which can then be analyzed for DNA and mRNA expression, protein levels, and other molecular characteristics.

Moreover, the automated analysis of TMAs is a key innovation in the field of biotechnology, enabling researchers to process large amounts of data efficiently and accurately. This technology has significant implications for molecular diagnostics and diagnostics development, as it can help identify biomarkers for early disease detection and personalized treatment. The TMA market is driven by the increasing cancer burden and the need for more effective therapeutic strategies. Prostate cancer, for instance, is a major focus of TMA research due to its high incidence and mortality rates. TMAs have been instrumental in identifying new drug targets and biomarkers for prostate cancer, leading to improved clinical outcomes. The Pathology Innovation Incubator is a leading organization in the field of TMA research and development. They specialize in the application of TMA technology to various clinical and research applications, including drug discovery and biomarker identification. Their work has led to significant advancements in the field of molecular diagnostics and personalized medicine. In conclusion, the TMA market is a vital component of molecular pathology and cancer research. Its ability to provide insights into gene expression, protein localization, and molecular markers makes it an essential tool for understanding tumor heterogeneity and identifying biomarkers for clinical outcomes, therapeutic targets, and prognostic indicators.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• End-user
  • Hospitals
  • Clinics
  • Diagnostics centers
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period. In the realm of cancer research and diagnostics, the utilization of tissue microarrays (TMAs) has gained significant traction. These arrays facilitate the analysis of numerous cancer samples on a single slide through a high-throughput process, enabling the examination of proteins and genes crucial for cancer diagnosis. Hospitals, as major end-users, greatly benefit from this technology due to its pivotal role in disease diagnosis and research. The ability to analyze thousands of tumor samples concurrently allows for efficient assessment of biomarkers, which can inform treatment decisions in oncology.

Get a glance at the market share of various segments Download the PDF Sample

The hospitals segment was valued at USD 2.69 billion in 2018. Furthermore, hospitals maintain archival tissue blocks for extended periods, typically up to 20 years, providing an abundant resource for constructing TMAs. This long-term availability of samples bolsters the potential for retrospective studies linked to patient outcomes, thereby underscoring the importance of TMAs in clinical settings. In the realm of drug discovery, TMAs are instrumental in drug testing and biologics development, as well as antigen identification through immunostaining techniques. Healthcare diagnostic facilities also leverage TMAs for spectroscopic analysis, expanding the scope of diagnostic possibilities.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, the market is experiencing significant growth due to substantial investments in healthcare research and testing, particularly in the United States. Pharmaceutical companies are increasingly focusing on drug discovery and development, which relies heavily on advanced molecular biology techniques like tissue microarrays. Furthermore, the high prevalence of chronic diseases, such as cancer, in North America necessitates extensive research and diagnostics. Consequently, techniques such as microarray technologies, including Fluorescent in-situ hybridization (FISH), Northern blotting, Western blotting, gene expression profiling, SNP detection, comparative genomic hybridization, and sequencing bioinformatics, are extensively used. Next-generation sequencing is also gaining popularity for its ability to generate vast amounts of genetic data. These techniques facilitate lead discovery and clinical assessment, ultimately contributing to the growth of the tissue microarray market in North America.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

A growing number of cancer cases worldwide is notably driving market growth. Cancer incidence is on the rise worldwide, with approximately 20% of the global population developing cancer during their lifetime, according to the International Agency for Research on Cancer (IARC). This statistic translates to 12.5% of men and 9.09% of women succumbing to the disease. The aging population and socio-economic risk factors, such as unhealthy diets, sedentary lifestyles, tobacco use, and excessive alcohol consumption, are the primary contributors to the increasing cancer prevalence.

Among all cancers, breast cancer is the most frequently diagnosed among women. Moreover, the global cancer market is witnessing significant growth due to the increasing burden of the disease and the subsequent demand for advanced treatment modalities. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

The rising popularity of personalized medicines is the key trend in the market. Microarray technology, including tissue microarrays, is gaining significance in the healthcare industry due to its ability to enhance automation and increase sample throughput in various applications, such as cancer research and personalized medicine. Imaging techniques and data analysis are integral components of microarray technology, enabling precise identification of biomarkers for disease diagnosis and drug development. The rising incidence of cancer and the growing focus on precision medicine and personalized treatment plans are driving the demand for advanced microarray technologies. In the field of oncology, microarray technology is utilized for biomarker research and clinical trials, facilitating the development of targeted therapies and improving patient outcomes.

Furthermore, microarray technology is also finding applications in other medical fields, including neurology and cardiology, to study genetic variations and inherited syndromes, contributing to the advancement of disease diagnosis and treatment. Digital pathology, which involves the application of imaging techniques and data analysis to histological samples, is another area where microarray technology is making a significant impact. The use of antibodies and other advanced tools in microarray technology is further expanding its applications and enhancing its accuracy and efficiency. In summary, microarray technology is a valuable tool in the healthcare industry, facilitating early disease detection, targeted drug development, and personalized treatment plans. Its role in genetic research and the diagnosis and treatment of chronic diseases, particularly cancer, is becoming increasingly important.  Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

The high cost of instruments is the major challenge that affects the growth of the market. Tissue microarrays (TMAs) have become essential tools in molecular pathology for studying gene expression and protein localization in various tissues, particularly in oncology research. TMAs allow for the analysis of large numbers of tissue samples using a single slide, facilitating the identification of tumor heterogeneity, biomarkers, clinical outcomes, therapeutic targets, and prognostic indicators. However, the adoption of TMAs is hindered by their high cost, both in procurement and maintenance. Advanced TMA instruments require significant investment due to their specialized features.

Additionally, regulatory compliance for portable immunodiagnostics, such as point-of-care (POC) testing products used for gene testing, increases their maintenance costs. For large-scale studies, reducing the cost-per-feature becomes crucial. To achieve this, systems must accommodate more features per chip, thereby decreasing the overall cost per feature. Tissue microarray technology offers valuable insights into genetic abnormalities and drug efficacy in clinical settings, making it an indispensable resource for researchers and clinicians. Hence, the above factors will impede the growth of the market during the forecast period

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Agilent Technologies Inc.: The company offers tissue microarray that are designed with 2.1 KB genome-wide median probe spacing and enhanced coverage on known genes, promoters, miRNAs, PAR and telomeric regions, under the brand name of SurePrint G3 Human CGH.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Arrayit Corp.
• Bio Rad Laboratories Inc.
• Bio Techne Corp.
• Enzo Biochem Inc.
• Illumina Inc.
• Molecular Device LLC
• OriGene Technologies Inc.
• Pantomics Inc.
• Perkin Elmer Inc.
• PhalanxBio Inc.
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified. It is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

The Tissue Microarray (TMA) market is witnessing significant growth due to its increasing application in molecular pathology, particularly in the field of oncology research. TMAs enable the analysis of gene expression and protein localization in a high-throughput manner, making them valuable tools for identifying molecular markers and biomarkers related to tumor heterogeneity, clinical outcomes, therapeutic targets, and prognostic indicators. In the realm of cancer research, TMAs have been instrumental in understanding genetic abnormalities and their role in drug efficacy, clinical settings, and cancer prevalence. They are used extensively in biomarker research and drug development, facilitating the discovery of new targets for cancer treatment. TMAs are also utilized in various clinical settings, including neurology, cardiology, and infectious diseases, for the analysis of protein expression, immunostaining, antigen identification, and DNA/mRNA analysis. Automation and imaging techniques have further enhanced the capabilities of TMAs, enabling automated analysis and data processing for precision and personalized medicine.

Moreover, the market encompasses various technologies such as immunohistochemistry (IHC), next-generation sequencing (NGS), DNA microarray, and digital pathology. These techniques facilitate the analysis of various clinical samples, including paraffin blocks, tissue cores, and frozen tissue arrays. The TMA market holds immense potential for pharmaceutical companies, biotechnology firms, and clinical diagnostic facilities, as they enable lead discovery, clinical assessment, and drug testing for various diseases, including cancer and neurological disorders. The market is expected to grow significantly due to the increasing cancer burden and the need for innovative diagnostic methods and array-based technology for disease gene discovery and heterogeneous cancers.

Download PDF Sample

What are the Key Data Covered in this Market Forecast Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market's competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch